The Global Clostridium Diagnostics Industry is on a trajectory for exceptional growth, projected to achieve an impressive Compound Annual Growth Rate (CAGR) of 12.2% from 2022 to 2032, increasing its market value from US$ 2.5 billion to US$ 7.8 billion. Notably, the market has already demonstrated substantial growth with a CAGR of 13.6% from 2015 to 2021.
This surge in market expansion is attributed to a heightened focus on raising awareness about clostridium-related illnesses and their increasing prevalence. Stakeholders across the healthcare sector are diligently working to combat these challenges, thus stimulating market growth.
A key factor driving this growth is the intensified commitment of industry players to develop and provide effective vaccines. For example, in March 2022, Japan inaugurated a state-of-the-art research center with a substantial budget of US$ 1.6 billion. This center is a vital component of a larger initiative aimed at combatting infectious diseases. Under the supervision of SCARDA (Strategic Center for Advanced Research and Development in Asia), this facility will establish a flagship Research and Development (R&D) site, fostering innovative collaborations and allocating funds for critical R&D projects.
Awareness campaigns are expected to play important role in driving the Industry during the forecast period. For instance, the ‘See C. diff’ campaign, launched by Peggy Lillis Foundation in December 2020, attained its objective by reaching more than 250,000 Americans. The organization launched the ‘See C. diff’ to commemorate C.diff Awareness Month in 2019, and reached about 80,000 people.
Request a Sample Copy of This Report Now.
https://www.futureIndustryinsights.com/reports/sample/rep-gb-15203
The launch of new vaccines in the Industry is another vital factor driving the Industry during the forecast period. For instance, in August 2021, Huvepharma Canada Corporation Inc. launched a new vaccine that has been shown to be effective against necrotic enteritis (NE) due to Clostridium perfringens type A in broiler chickens.
In addition, emerging companies such as, Acurx Pharmaceuticals, Cubist Pharmaceuticals, Endo Aesthetics, Avisa Pharma, and MGB Bio Pharma are expected to make a significant contribution in developing the Industry during the forecast period. However, lack of awareness and scarcity of resources in developing countries are expected to hamper the Industry growth during the forecast period. Also, the high costs involved in R&D and vaccine manufacturing are expected to be other factors hindering the Industry growth in the assessment period.
However, growing partnerships among players are projected to counter the hampering factors and boost the Industry. For instance, in March 2021, Peggy Lillis Foundation for Clostridium difficile infections announced a partnership with Ferring Pharmaceutical through a new sponsorship to assist new and existing patient advocacy initiatives.
Key Takeaways from the Industry Study:
- The immunoassays technology is expected to dominate the Global Clostridium Diagnostics Industry at a CAGR of 11.6% during 2022-2032
- The clostridium diagnostics Industry in the U.S is anticipated to display a CAGR of 11.8% during the forecast period
- The U.K clostridium diagnostics Industry is predicted to hold a Industry value worth US$ 330 Million by 2032
- The Japanese clostridium diagnostics Industry is estimated at a CAGR of 11.1% during the forecast period.
“Growing launch of new vaccines by various players of the Industry along with the increasing popularity of awareness campaigns as a useful tool for Industry growth is expected to play a significant role in driving the Industry during the forecast period,” says an FMI analyst.
Methodology Details Just a Click Away!
https://www.futureIndustryinsights.com/request-report-methodology/rep-gb-15203
Competition Analysis
- Abbott Laboratories
- F. Hoffmann La-Roche AG
- Siemens AG
- Becton, Dickinson & Company
- Beckman Coulter Inc.
- Sysmex India Pvt. Ltd.
- Thermo Fisher Scientific Inc.
- Fujirebio US Inc.
- BioMerieux S.A
- Diazyme Laboratories Inc.
Key Segments Profiled In the Global Clostridium Diagnostics Industry
Global Clostridium Diagnostics Industry by Technology:
- Immunoassays-based Clostridium Diagnostics
- Molecular Clostridium Diagnostics
Global Clostridium Diagnostics Industry by End User:
- Clostridium Diagnostics in Hospitals
- Clostridium Diagnostics in Government Diagnostics Laboratories
- Clostridium Diagnostics in Independent Laboratories
Global Clostridium Diagnostics Industry by Product:
- Clostridium Difficile Diagnostics
- Clostridium Perfringens Diagnostics
- Clostridium Botulinum Diagnostics
- Clostridium Tetani Diagnostics
- Clostridium Sordell Diagnostics
Access Exclusive Industry Insights – Purchase Now!
https://www.futureIndustryinsights.com/checkout/15203
Author
Sabyasachi Ghosh (Associate Vice President at Future Industry Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Industry Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Industry Insights (FMI)
Future Industry Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the Industry. FMI stands as the leading global provider of Industry intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals Industrys. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Industry Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futureIndustryinsights.com
Website: https://www.futureIndustryinsights.com
LinkedIn| Twitter| Blogs | YouTube